Synopsis
Synopsis
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 19,583 Rp
2. 2-(3-benzoylphenyl)propionic Acid
3. Alrheumat
4. Alrheumum
5. Benzoylhydratropic Acid
6. Orudis
7. Profenid
8. Rp 19583
9. Rp, 19,583
10. Rp-19583
11. Rp19583
1. 22071-15-4
2. 2-(3-benzoylphenyl)propanoic Acid
3. Orudis
4. 2-(3-benzoylphenyl)propionic Acid
5. Actron
6. Capisten
7. Oruvail
8. M-benzoylhydratropic Acid
9. Alrheumat
10. Ketoprofene
11. Profenid
12. Aneol
13. 3-benzoylhydratropic Acid
14. Alrheumun
15. Epatec
16. Iso-k
17. Orudis (tn)
18. Rp-19583
19. Ketoprofeno
20. Ketoprophene
21. 2-[3-(phenylcarbonyl)phenyl]propanoic Acid
22. Ketorin
23. Sector
24. (rs)-ketoprofen
25. 2-(m-benzoylphenyl)propionic Acid
26. Actron Ketoprofen
27. Racemic Ketoprofen
28. Benzeneacetic Acid, 3-benzoyl-.alpha.-methyl-
29. 3-benzoyl-alpha-methylbenzeneacetic Acid
30. Ru 4733
31. Ketoprofen (actron)
32. Chebi:6128
33. Chembl571
34. Nsc-758144
35. Propionic Acid, 2-(3-benzoylphenyl)-
36. (s)-ketoprofen;dexketoprofen
37. 19583 Rp
38. Hydratropic Acid, M-benzoyl-
39. L'acide (benzoyl-3-phenyl)-2-propionique
40. Mls000079024
41. Idea-033
42. R.p. 19,583
43. 90y4qc304k
44. Orudis Kt
45. 1189508-77-7
46. 19583rp
47. Ru-4733
48. Kefenid
49. Ketopron
50. Menamin
51. Meprofen
52. Orugesic
53. Oscorel
54. Smr000040181
55. Fastum
56. Ketoprofen 100 Microg/ml In Acetonitrile
57. Lertus
58. Toprec
59. Toprek
60. Dexal
61. Dsstox_cid_771
62. R.p. 19583
63. Racemic-ketoprofen
64. Dsstox_rid_75783
65. Dsstox_gsid_20771
66. Ketoprofenum
67. Rp 19583
68. Ketoprofene [inn-french]
69. Ketoprofenum [inn-latin]
70. Ketoprofeno [inn-spanish]
71. Ketoprofen (+-)
72. (+-)-m-benzoylhydratropic Acid
73. Benzeneacetic Acid, 3-benzoyl-alpha-methyl-
74. Sr-01000075949
75. Rac Ketoprofen
76. Ccris 4508
77. (+-)-3-benzoyl-alpha-methylbenzeneacetic Acid
78. (+/-)-m-benzoylhydratropic Acid
79. (+) Ketoprofen
80. Ncgc00016757-01
81. Ketoprofen ,(s)
82. Acide (benzoyl-3-phenyl)-2-propionique [french]
83. Prestwick_617
84. Einecs 244-759-8
85. 2-[3-(benzoyl)phenyl]propanoic Acid
86. Cas-22071-15-4
87. Mfcd00055790
88. Nexcede
89. Ketoprofen-13c-d3
90. 2-(3-benzoylphenyl)-propionic Acid
91. Hydratropic Acid, M-benzoyl-, (+-)-
92. Acide (benzoyl-3-phenyl)-2-propionique
93. Spectrum_001309
94. Ketoprofen [mi]
95. Opera_id_509
96. Ketoprofen [inn]
97. Ketoprofen [jan]
98. Prestwick0_000219
99. Prestwick1_000219
100. Prestwick2_000219
101. Prestwick3_000219
102. Spectrum2_000956
103. Spectrum3_001479
104. Spectrum4_000028
105. Spectrum5_001254
106. Ketoprofen [usan]
107. M-benzoyl-hydratropic Acid
108. Ketoprofen [vandf]
109. Epitope Id:131783
110. K 1751
111. Ketoprofen [mart.]
112. Schembl2896
113. Ketoprofen [who-dd]
114. (+/-)-ketoprofen
115. Lopac0_000686
116. Oprea1_117113
117. Bspbio_000237
118. Bspbio_003037
119. Kbiogr_000435
120. Kbioss_001789
121. 22161-86-0
122. Mls000028446
123. Mls001201752
124. Mls001306444
125. Mls002548889
126. Mls006011967
127. Bidd:gt0443
128. Divk1c_000598
129. Spectrum1501215
130. Unii-90y4qc304k
131. Spbio_000952
132. Spbio_002158
133. Benzeneacetic Acid, 3-benzoyl-alpha-methyl-, (+-)-
134. Bpbio1_000261
135. Gtpl4795
136. Ketoprofen (jp17/usp/inn)
137. Ketoprofen [green Book]
138. Ketoprofen, >=98% (tlc)
139. Dtxsid6020771
140. Ketoprofen [ep Impurity]
141. Ketoprofen [orange Book]
142. Dkywvdodhfezim-uhfffaoysa-
143. Hms501n20
144. Kbio1_000598
145. Kbio2_001789
146. Kbio2_004357
147. Kbio2_006925
148. Kbio3_002537
149. 2-(3-benzoylphenyl)propanoicacid
150. Ketoprofen [ep Monograph]
151. Ketoprofen [usp Impurity]
152. Ninds_000598
153. Hms1568l19
154. Hms1921b12
155. Hms2089b16
156. Hms2092l19
157. Hms2095l19
158. Hms2234h16
159. Hms3259i05
160. Hms3262i13
161. Hms3372m08
162. Hms3373g09
163. Hms3649n10
164. Hms3655c15
165. Hms3712l19
166. Hms3884k04
167. Ketoprofen [usp Monograph]
168. Pharmakon1600-01501215
169. Bcp23428
170. Hy-b0227
171. 2-(3'-benzoylphenyl)propionic Acid
172. 2-(3-benzoylphenyl) Propionic Acid
173. Alpha(3-benzoylphenyl)propionic Acid
174. Tox21_110594
175. Tox21_200847
176. Tox21_500686
177. (.+/-.)-m-benzoylhydratropic Acid
178. 2-(3-benzoylphenyl) Propionoic Acid
179. Alpha-(m-benzoylphenyl)propionic Acid
180. Bdbm50022271
181. Ccg-39685
182. Nsc758144
183. S1645
184. Stl450995
185. (r)-(-)-ketoprofen-[13c,d3]
186. 2-(3-benzoylphenyl)propanoic Acid #
187. Alpha-(3-benzoylphenyl)propionic Acid
188. Akos007930512
189. Alpha-(m-benzoylphenyl) Propionic Acid
190. Ketoprofen 100 Microg/ml In Methanol
191. Tox21_110594_1
192. Ac-1486
193. Bcp9000810
194. Db01009
195. Ketoprofen [usan:usp:inn:ban:jan]
196. Ks-5031
197. Lp00686
198. Nc00459
199. Nsc 758144
200. Sdccgsbi-0050664.p004
201. Idi1_000598
202. (rs)-2-(3-benzoylphenyl)propanoic Acid
203. Ncgc00015578-02
204. Ncgc00015578-03
205. Ncgc00015578-04
206. Ncgc00015578-05
207. Ncgc00015578-07
208. Ncgc00015578-08
209. Ncgc00015578-10
210. Ncgc00015578-12
211. Ncgc00015578-23
212. Ncgc00094043-01
213. Ncgc00094043-02
214. Ncgc00094043-03
215. Ncgc00094043-04
216. Ncgc00258401-01
217. Ncgc00261371-01
218. Bk166172
219. ((c)i)-ketoprofen-d4(propionic-d4 Acid)
220. 3-benzoyl-.alpha.-methylbenzeneacetic Acid
221. Bcp0726000302
222. Sbi-0050664.p003
223. (+/-)-2-(3-benzoylphenyl)propionic Acid
224. L''acide (benzoyl-3-phenyl)-2-propionique
225. Unm-0000306100
226. Ab00052249
227. Am20060549
228. Eu-0100686
229. Ft-0602834
230. Ft-0670646
231. Ft-0670647
232. K0038
233. Ketoprofen, Meets Usp Testing Specifications
234. Orudis, Profenid, Dexal, Keduril, Ketofen,
235. Sw196784-3
236. Bim-0050664.0001
237. C01716
238. D00132
239. D78110
240. Ketoprofen, Vetranal(tm), Analytical Standard
241. Ab00052249-17
242. Ab00052249-19
243. Ab00052249-20
244. Ab00052249_21
245. Ab00052249_22
246. 071k154
247. A815896
248. Q409192
249. Q-201268
250. Sr-01000075949-1
251. Sr-01000075949-6
252. Sr-01000075949-9
253. (.+/-.)-3-benzoyl-.alpha.-methylbenzeneacetic Acid
254. Brd-a97739905-001-05-9
255. Brd-a97739905-001-15-8
256. Sr-01000075949-18
257. F2173-0960
258. Z1695709452
259. (+/-)-3-benzoyl-.alpha.-methylbenzeneacetic Acid
260. Ketoprofen, British Pharmacopoeia (bp) Reference Standard
261. Ketoprofen, European Pharmacopoeia (ep) Reference Standard
262. Ketoprofen, United States Pharmacopeia (usp) Reference Standard
263. N-fmoc-3-amino-4-(4-tert-butoxy-phenyl)-butyricacid
264. Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material
265. 154907-35-4
| Molecular Weight | 254.28 g/mol |
|---|---|
| Molecular Formula | C16H14O3 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 254.094294304 g/mol |
| Monoisotopic Mass | 254.094294304 g/mol |
| Topological Polar Surface Area | 54.4 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 331 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Ketoprofen |
| PubMed Health | Ketoprofen (By mouth) |
| Drug Classes | Analgesic, Antimigraine, Antirheumatic, Central Nervous System Agent, Musculoskeletal Agent |
| Drug Label | Ketoprofen is a non-steroidal anti-inflammatory drug. The chemical name for ketoprofen is 2-(3-benzoylphenyl)-propionic acid with the following structural formula:C16H14O3M.W. 254.29It has a pKa of 5.94 in methanol: water (3:1) an... |
| Active Ingredient | Ketoprofen |
| Dosage Form | Capsule; Capsule, extended release |
| Route | Oral |
| Strength | 200mg; 25mg; 150mg; 75mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Teva; Dorado Pharma; Mylan |
| 2 of 2 | |
|---|---|
| Drug Name | Ketoprofen |
| PubMed Health | Ketoprofen (By mouth) |
| Drug Classes | Analgesic, Antimigraine, Antirheumatic, Central Nervous System Agent, Musculoskeletal Agent |
| Drug Label | Ketoprofen is a non-steroidal anti-inflammatory drug. The chemical name for ketoprofen is 2-(3-benzoylphenyl)-propionic acid with the following structural formula:C16H14O3M.W. 254.29It has a pKa of 5.94 in methanol: water (3:1) an... |
| Active Ingredient | Ketoprofen |
| Dosage Form | Capsule; Capsule, extended release |
| Route | Oral |
| Strength | 200mg; 25mg; 150mg; 75mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Teva; Dorado Pharma; Mylan |
For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
FDA Label
Treatment of musculoskeletal and connective tissue pain
Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
M02AA10
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
M - Musculo-skeletal system
M01 - Antiinflammatory and antirheumatic products
M01A - Antiinflammatory and antirheumatic products, non-steroids
M01AE - Propionic acid derivatives
M01AE03 - Ketoprofen
M - Musculo-skeletal system
M02 - Topical products for joint and muscular pain
M02A - Topical products for joint and muscular pain
M02AA - Antiinflammatory preparations, non-steroids for topical use
M02AA10 - Ketoprofen
Absorption
Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Route of Elimination
In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
Clearance
Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 50 mg)]
Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 200 mg)]
0.08 L/kg/h
0.7 L/kg/h [alcoholic cirrhosis patients]
Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
Ketoprofen has known human metabolites that include Ketoprofen glucuronide.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Conventional capsules: 1.1-4 hours
Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)
The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Doshion Polyscience
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Granulation
Controlled & Modified Release
Taste Masking
Direct Compression
Lubricants & Glidants
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Thickeners and Stabilizers
Empty Capsules
Solubilizers
Topical
Chewable & Orodispersible Aids
API Stability Enhancers
Parenteral
Co-Processed Excipients
Vegetarian Capsules
Emulsifying Agents
Surfactant & Foaming Agents
Coloring Agents
Rheology Modifiers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
61
PharmaCompass offers a list of Ketoprofen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ketoprofen manufacturer or Ketoprofen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ketoprofen manufacturer or Ketoprofen supplier.
PharmaCompass also assists you with knowing the Ketoprofen API Price utilized in the formulation of products. Ketoprofen API Price is not always fixed or binding as the Ketoprofen Price is obtained through a variety of data sources. The Ketoprofen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Orudis KT manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orudis KT, including repackagers and relabelers. The FDA regulates Orudis KT manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orudis KT API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orudis KT manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Orudis KT supplier is an individual or a company that provides Orudis KT active pharmaceutical ingredient (API) or Orudis KT finished formulations upon request. The Orudis KT suppliers may include Orudis KT API manufacturers, exporters, distributors and traders.
click here to find a list of Orudis KT suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Orudis KT DMF (Drug Master File) is a document detailing the whole manufacturing process of Orudis KT active pharmaceutical ingredient (API) in detail. Different forms of Orudis KT DMFs exist exist since differing nations have different regulations, such as Orudis KT USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orudis KT DMF submitted to regulatory agencies in the US is known as a USDMF. Orudis KT USDMF includes data on Orudis KT's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orudis KT USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orudis KT suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Orudis KT Drug Master File in Japan (Orudis KT JDMF) empowers Orudis KT API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Orudis KT JDMF during the approval evaluation for pharmaceutical products. At the time of Orudis KT JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Orudis KT suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Orudis KT Drug Master File in Korea (Orudis KT KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Orudis KT. The MFDS reviews the Orudis KT KDMF as part of the drug registration process and uses the information provided in the Orudis KT KDMF to evaluate the safety and efficacy of the drug.
After submitting a Orudis KT KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Orudis KT API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Orudis KT suppliers with KDMF on PharmaCompass.
A Orudis KT CEP of the European Pharmacopoeia monograph is often referred to as a Orudis KT Certificate of Suitability (COS). The purpose of a Orudis KT CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Orudis KT EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Orudis KT to their clients by showing that a Orudis KT CEP has been issued for it. The manufacturer submits a Orudis KT CEP (COS) as part of the market authorization procedure, and it takes on the role of a Orudis KT CEP holder for the record. Additionally, the data presented in the Orudis KT CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Orudis KT DMF.
A Orudis KT CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Orudis KT CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Orudis KT suppliers with CEP (COS) on PharmaCompass.
A Orudis KT written confirmation (Orudis KT WC) is an official document issued by a regulatory agency to a Orudis KT manufacturer, verifying that the manufacturing facility of a Orudis KT active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Orudis KT APIs or Orudis KT finished pharmaceutical products to another nation, regulatory agencies frequently require a Orudis KT WC (written confirmation) as part of the regulatory process.
click here to find a list of Orudis KT suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orudis KT as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Orudis KT API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Orudis KT as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Orudis KT and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orudis KT NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Orudis KT suppliers with NDC on PharmaCompass.
Orudis KT Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orudis KT GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orudis KT GMP manufacturer or Orudis KT GMP API supplier for your needs.
A Orudis KT CoA (Certificate of Analysis) is a formal document that attests to Orudis KT's compliance with Orudis KT specifications and serves as a tool for batch-level quality control.
Orudis KT CoA mostly includes findings from lab analyses of a specific batch. For each Orudis KT CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orudis KT may be tested according to a variety of international standards, such as European Pharmacopoeia (Orudis KT EP), Orudis KT JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orudis KT USP).
